Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Yorvipath (palopegteriparatide) is indicated for the treatment of hypoparathyroidism in adults.
• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Composite Primary Efficacy Endpoint: At week 26, 79% (48/61) of participants treated with TransCon PTH achieved normal albumin-adjusted serum calcium levels, independence from conventional therapy, and no increase in study drug, compared to 5% (1/21) in the placebo group (p < 0.0001).
• Health-Related Quality of Life (SF-36) and Hypoparathyroidism-Related Symptoms (HPES): TransCon PTH resulted in significant improvements in the SF-36 Physical Functioning subscale (p = 0.0347) and in all key secondary endpoint HPES domain scores (all p < 0.01), indicating enhanced well-being and reduced hypoparathyroidism-related symptoms.
• Independence from Conventional Therapy: 93% (57/61) of participants on TransCon PTH achieved independence from conventional therapy, with no comparative data provided for the placebo group.
• Adverse Events: 82% (50/61) of participants on TransCon PTH experienced adverse events, with most being mild (46%) or moderate (46%) in severity. In the placebo group, 100% (21/21) experienced adverse events, though severity details were not provided.
• Withdrawals: There were no study drug-related withdrawals in the TransCon PTH group. No comparative data were provided for the placebo group.
• There is no population types or subgroups information available in the reviewed studies.